Profile data is unavailable for this security.
About the company
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.
- Revenue in USD (TTM)205.45m
- Net income in USD3.60m
- Incorporated2018
- Employees248.00
- LocationLifeVantage Corp3300 TRIUMPH BLVD, SUITE 700LEHI 84043United StatesUSA
- Phone+1 (801) 432-9000
- Fax+1 (302) 636-5454
- Websitehttps://www.lifevantage.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV | 6.77m | -41.97m | 79.66m | 37.00 | -- | 1.56 | -- | 11.77 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 80.68m | 225.00 | -- | -- | -- | 9.41 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Passage Bio Inc | 0.00 | -102.06m | 80.71m | 58.00 | -- | 0.6468 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 80.99m | 4.00 | -- | -- | -- | 145.22 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.49m | 81.98m | 17.00 | -- | 3.04 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 82.95m | 165.00 | -- | 4.92 | -- | 2.68 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| LifeVantage Corp | 205.45m | 3.60m | 83.44m | 248.00 | 23.31 | 3.11 | 11.47 | 0.4061 | 0.2818 | 0.2818 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Chimerix Inc | 41.00k | -82.59m | 85.41m | 72.00 | -- | 0.4906 | -- | 2,083.13 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| MDxHealth SA - ADR | -100.00bn | -100.00bn | 85.68m | 258.00 | -- | 11.89 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 85.93m | 74.00 | -- | -- | -- | 62.27 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 838.12k | 6.51% |
| Sudbury Capital Management LLCas of 26 Feb 2024 | 749.33k | 5.82% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 459.18k | 3.57% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 313.38k | 2.44% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 221.97k | 1.73% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 202.66k | 1.58% |
| Geode Capital Management LLCas of 31 Dec 2023 | 116.79k | 0.91% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 96.36k | 0.75% |
| Perkins Capital Management, Inc.as of 31 Dec 2023 | 76.11k | 0.59% |
| Empowered Funds LLCas of 31 Dec 2023 | 70.46k | 0.55% |
